Table 1.
Baseline characteristics of women included in the study according to status of antiretroviral therapy after delivery.
| Characteristic | Total n = 206 | Stopped therapy n = 59 | Continued therapy n = 147 | P* |
|---|---|---|---|---|
| Race/ethnicity | .43 | |||
| White | 22 (10.7%) | 8 (13.6%) | 14 (9.5%) | |
| African American | 98 (47.6%) | 29 (49.2%) | 69 (46.9%) | |
| Latina | 75 (36.4%) | 21 (35.6%) | 54 (36.7%) | |
| Other | 11 (5.3%) | 1 (1.7%) | 10 (6.8%) | |
| CD4+ lymphocyte count | .03 | |||
| 350–500 cells/uL | 84 (40.9%) | 17 (28.8%) | 67 (45.6%) | |
| >500 cells/uL | 122 (59.2%) | 42 (71.2%) | 80 (54.4%) | |
| CDC Classified events | ||||
| Class B or worse | 59 (28.6%) | 15 (25.4%) | 44 (29.9%) | .52** |
| Class C | 6 (2.9%) | 2 (3.4%) | 4 (2.7%) | .80** |
| Mean enrollment CD4+ lymphocyte count | 603 | 680.3 ± 63.9 | 572.5 ± 30.5 | .004 |
| Mean enrollment CD4+ percentage | 34.2% ± 1.9 | 31.8% ± 1.4 | .06 | |
| Mean gestational age (weeks) | 16.1 | 16.1 ± 1.9 | 16.1 ± 1.2 | .97 |
| Mean enrollment HIV RNA (log10) | 2.63 ± 0.5 | 3.00 ± 0.3 | .23 | |
| Mean maternal age | 25.9 ± 1.2 | 27.7 ± 1.0 | .04 | |
| Therapy during pregnancy | ||||
| Zidovudine monotherapy⋀ | 103 (50%) | 41 (40%) | 62 (60%) | |
| Combination therapy | 100 (49%) | 18 (18%) | 82 (82%) |
* T test comparing means or proportions except as noted. ** Chi square test used. ⋀ Three additional women received monotherapy with other agents, one with nevirapine and two with didanosine.